Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.39 |
| ▸ | BID | P55957 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.38 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793440 | 0.80 | ASAH1 (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL337266 | 0.80 | ASAH1 (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL535094 | 0.80 | ASAH1 (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL535029 | 0.80 | ASAH1 (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL534984 | 0.80 | ASAH1 (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL18206302 | 0.80 | ASAH1 (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL535030 | 0.78 | ASAH1 (0.64) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL8907627 | 0.75 | KCNMA1 (0.45) | MAPTKMT2AHPGD | |
| SCHEMBL534955 | 0.73 | ASAH1 (0.58) | MAPTKMT2AMEN1ALDH1A1ASAH1 | |
| SCHEMBL18932961 | 0.73 | ASAH1 (0.58) | MAPTKMT2AMEN1ALDH1A1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309336-B1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | BIOSOURCE PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1309336-A4 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | MICROLOGIX BIOTECH INC (CA) | 2005-01-05 | — | — | EP | disclosed |
| US-6737403-B2 | CULTURING MICROORGANISM STREPTOMYCES VIRIDOCHROMOGENES, SSP. KOMABENSIS (ATCC 29814) IN CULTURE MEDIUM, ISOLATING LASPARTOMYCIN, CLEAVING LIPOPHILIC FRAGMENT FROM LASPARTOMYCIN, THEREBY YIELDING LASPARTOMYCIN CORE PEPTIDE | MICROLOGIX BIOTECH INC. (CA) | 2004-05-18 | — | — | US | disclosed |
| EP-1309336-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | Micrologix Biotech, Inc. (CA) | 2003-05-14 | — | — | EP | disclosed |
| US-6511962-B1 | Intermediates useful for synthesizing laspartomycin derivatives as well as the laspartomycin derivatives | MICROLOGIX BIOTECH INC. (CA) | 2003-01-28 | — | — | US | disclosed |
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | BIOSOURCE PHARM, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002005838-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | VIP, LAS1L, PREP | MAPT 4251/4885KMT2A 4806/4885MEN1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.